Low-dose IVIG shows similar efficacy to standard-dose IVIG in adults with AChR-positive generalized myasthenia gravis.
Low-Dose IVIG Works as Well as High-Dose for MG
This prospective single-center cohort study evaluated low-dose versus standard-dose intravenous immunoglobulin (IVIG) in 34 adults with AChR…
A much smaller dose of IVIG may relieve severe muscle weakness in myasthenia gravis just as well as the standard high dose—cutting treatment…
Efgartigimod improved MG-ADL and QMG scores in 81 Chinese patients with generalized myasthenia gravis.
Many Myasthenia Gravis Patients Need Just One Treatment Cycle
This single-center, retrospective analysis evaluated efgartigimod in 81 Chinese patients with generalized myasthenia gravis. At week 4, 65 p…
Most patients with myasthenia gravis controlled symptoms after a single treatment cycle, with fewer infusions possible for some.
Efgartigimod shows homogeneous efficacy across sexes in AChR-Ab+ generalized myasthenia gravis.
New Hope for All Myasthenia Gravis Patients
This post hoc, sex-specific subgroup analysis of the ADAPT Phase 3 RCT evaluated efgartigimod in 86 females and 43 males with AChR-Ab+ gener…
A new treatment for myasthenia gravis works equally well for women and men, offering the same relief from severe muscle weakness regardless …
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …